Study of Low-Dose Radiotherapy Combined with Chemoimmunotherapy for Adults Aged 18 to 70 With Nasopharyngeal Carcinoma and Liver Metastasis

What this Trial Is About

Researchers are evaluating the effects of adding low-dose radiotherapy to chemoimmunotherapy as a first treatment for patients with nasopharyngeal carcinoma who have liver metastasis. This phase 2 study aims to understand how well this combination works and its side effects in this patient group. The study focuses on patients aged 18 to 70 years who have specific types of nasopharyngeal cancer and liver metastases. The treatment involves delivering low-dose radiotherapy 1.4 Gy daily for 5 days targeted at liver metastases before starting chemoimmunotherapy. The chemoimmunotherapy includes gemcitabine 1000 mgm on days 1 and 8, cisplatin 80 mgm on day 1, and penpulimab 200 mg on day 1. Participants receive this combined treatment as the first-line therapy to assess its impact on cancer progression and survival. Participants will undergo various assessments during the study, including measuring tumor response according to RECIST criteria and monitoring blood counts and organ function. Researchers will track outcomes such as intrahepatic progression-free survival at one year, overall survival at two years, progression-free survival, response rates at 18 weeks, and adverse event rates over two years. The entire study period extends until June 2027, with planned follow-up to observe treatment effects and safety.

LDRT and Chemoimmunotherapy in NPC With Liver Metastasis